Strecker J, Jones S, Koopal B, et al. Engineering of CRISPR-Cas12b for human genome editing. Nat Commun. 2019;10(1):212. doi:10.1038/s41467-018-08224-4.

Pan D, Kobayashi A, Jiang P, et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science. 2018;359(6377):770-775. doi:10.1126/science.aao1710.

Han S, Zhao BS, Myers SA, Carr SA, He C, Ting AY. RNA-protein interaction mapping via MS2- or Cas13-based APEX targeting. Proc Natl Acad Sci U S A. 2020;117(36):22068-22079. doi:10.1073/pnas.2006617117.

Tothova Z, Krill-Burger JM, Popova KD, et al. Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. Cell Stem Cell. 2017;21(4):547-555.e8. doi:10.1016/j.stem.2017.07.015.

Patel SJ, Sanjana NE, Kishton RJ, et al. Identification of essential genes for cancer immunotherapy. Nature. 2017;548(7669):537-542. doi:10.1038/nature23477.

Maji B, Gangopadhyay SA, Lee M, et al. A High-Throughput Platform to Identify Small-Molecule Inhibitors of CRISPR-Cas9. Cell. 2019;177(4):1067-1079.e19. doi:10.1016/j.cell.2019.04.009.

Piccioni F, Younger ST, Root DE. Pooled Lentiviral-Delivery Genetic Screens. Curr Protoc Mol Biol. 2018;121:32.1.1-32.1.21. doi:10.1002/cpmb.52.

Guo X, Chavez A, Tung A, et al. High-throughput creation and functional profiling of DNA sequence variant libraries using CRISPR-Cas9 in yeast. Nat Biotechnol. 2018;36(6):540-546. doi:10.1038/nbt.4147.

Meyers RM, Bryan JG, McFarland JM, et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017;49(12):1779-1784. doi:10.1038/ng.3984.

Stolte B, Iniguez AB, Dharia NV, et al. Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in wild-type Ewing sarcoma. J Exp Med. 2018;215(8):2137-2155. doi:10.1084/jem.20171066.